Updated 2024-2025 Nuvaxovid COVID-19 Vaccine (NVX-CoV2705) receives authorization in the EU – Novavax
9 October 2024-Novavax, Inc. announced that the European Commission granted Marketing Authorization for Novavax’s updated 2024-2025 Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in… read more.
